New Wearable Sensor Spots Hidden Ketosis in Type 1 Diabetes

People with type 1 diabetes face a paradoxical threat called euglycemic ketosis: their ketone levels can rise dangerously while their blood sugar stays normal or in range. This makes the condition nearly invisible to standard glucose monitoring alone.

Ketosis becomes risky when several conditions combine—particularly the use of SGLT2 inhibitors (a class of diabetes medication), following a low-carbohydrate diet, and engaging in intense physical activity. A new case study highlights how quickly this situation can develop and why early detection matters.

A 30-year-old woman with type 1 diabetes using an automated insulin pump and the medication empagliflozin (an SGLT2 inhibitor) decided to adopt a low-carb diet and increase her exercise. She was also enrolled in a clinical trial testing a new wearable continuous ketone monitor (CKM).

Over a 14-hour period, her ketone sensor detected ketosis levels above 1.0 mmol/L, reaching as high as 2.9 mmol/L. Despite these elevated ketones, her continuous glucose monitor showed her blood sugar staying in target range—a textbook example of euglycemic ketosis.

Because the ketone sensor caught the problem early, her care team was able to guide her to add carbohydrates and adjust her insulin. She recovered safely with the sensor providing real-time feedback throughout.

Standard continuous glucose monitors only track blood sugar. They cannot detect ketone levels, leaving a critical blind spot for people at risk of euglycemic ketosis. Without dedicated ketone monitoring, such situations might go unrecognized until they progress to diabetic ketoacidosis—a serious medical emergency.

The combination of SGLT2 inhibitors, carbohydrate restriction, and exercise is increasingly common among people managing type 1 diabetes, making this risk relevant to many. A tool that catches ketosis early could prevent dangerous escalation.

This single case study cannot prove that continuous ketone monitoring should become standard care. However, it demonstrates that wearable ketone sensors are technically capable of detecting euglycemic ketosis in real time—and that early detection enabled safe intervention.

Researchers and clinicians are now considering whether continuous ketone monitoring might reduce the risk of diabetic ketoacidosis, especially for people using SGLT2 inhibitors or managing low-carb diets and exercise regimens. Further research will be needed to determine who would benefit most and whether continuous ketone monitoring should become part of routine care for higher-risk populations.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.